In addition to offering lower prices for GLP-1s, this model will provide patients with access to lifestyle support programs at no cost, which are intended to support medication adherence as well as increase GLP-1 effectiveness
How Does Semaglutide Interact with Dopamine Pathways
Precision targeted therapy with BLU-667 for RET-driven cancers
Daewoong Pharmaceutical is poised to enter this market with its innovative microneedle obesity treatment by 2028, aiming to revolutionize the sector by addressing the limitations of current therapies, especially in improving treatment adherencea significant challenge highlighted by Eli Lilly's CSO, Dr
2014;311:16 Krajnc N, Itariu B, Macher S, Marik W, Harreiter J, Michl M et al
Ching-Yang Cheng, M.D., from Chung Shan Medical University in Taichung, Taiwan, and colleagues conducted a retrospective cohort study using the TriNetX network from 2015 to 2023 for adults with T2DM who were new users of GLP-1 RAs or dipeptidyl peptidase-4 inhibitors (DPP-4is) to examine the risk for incident epilepsy